Posted by Michael Wonder on 17 Oct 2018
Further hepatitis C drug delay 'cruel'
18 October 2018 - PHARMAC's decision to extend consultation on introducing new hepatitis C drugs is cruel and devastating for patients, a Dunedin woman says.
Around 43% of hepatitis C patients are unable to take the drugs funded by PHARMAC, the Government's drug-buying agency.
In July at a summit held to mark World Hepatitis Day, Health Minister David Clark announced PHARMAC would begin public consultation on introducing two new ''pangenotypic'' medicines which would help those patients.
